LEEF:CA:CNSX-Leef Brands Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.265

Change

-0.03 (-8.62)%

Market Cap

USD 0.05B

Volume

0.14M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

-0.77 (-6.66%)

USD 2.72B
TRUL:CA Trulieve Cannabis Corp

-0.24 (-3.19%)

USD 1.31B
CL:CA Cresco Labs Inc

-0.09 (-6.12%)

USD 0.41B
GRIN:CA Grown Rogue International Inc

-0.01 (-1.10%)

USD 0.20B
PLTH:CA Planet 13 Holdings Inc

-0.01 (-1.85%)

USD 0.17B
AAWH-U:CA Ascend Wellness Holdings Inc.

-0.04 (-8.70%)

USD 0.09B
JUSH:CA Jushi Holdings Inc

-0.01 (-1.16%)

USD 0.08B
MRMD:CA MariMed Inc.

+0.01 (+3.13%)

USD 0.07B
AYR-A:CA Ayr Wellness Inc

-0.07 (-9.46%)

USD 0.07B
INNO:CA InnoCan Pharma Corporation

N/A

USD 0.06B

ETFs Containing LEEF:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.67% 16% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.67% 16% F 16% F
Trailing 12 Months  
Capital Gain 76.67% 91% A- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.67% 91% A- 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.94% 46% F 37% F
Dividend Return -10.94% 46% F 37% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.33% 75% C 61% D-
Risk Adjusted Return -30.96% 40% F 43% F
Market Capitalization 0.05B 84% B 95% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.